A study focused on the CD2 gene of breast cancer revealed that patients with high immune scores had improved OS, proving that the immune component of the immune microenvironment is a potential favorable factor in terms of the prognosis of BRCA patients [30]. This evidence concerns the gene CD2 and breast carcinoma.